JUNO THERAPEUTICS INC

Inactive Instrument

Juno Therapeutics Inc Stock

Equities

US48205A1097

Biotechnology & Medical Research

on all our subscriptions*

Exceptional extension!

Take advantage of the offer

* See conditions on site

Chart Juno Therapeutics Inc

Duration

Period

Style

Latest news about Juno Therapeutics Inc

Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	18-03-29	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	18-03-29	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	18-03-28	RE
Gilead Sciences : Sangamo in $3 billion gene-editing deal with Gilead	18-02-22	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	18-01-29	RE
Stocks hit record as senators reach deal to end shutdown	18-01-22	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	18-01-22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	18-01-22	RE
Novartis : FDA panel backs Novartis' pioneering new cancer gene therapy	17-07-12	RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies'	17-03-01	RE
Juno Therapeutics : Yahoo says about 32 million accounts accessed using 'forged cookies'	17-03-01	RE
Juno Therapeutics : Shares of Juno Therapeutics jump after FDA removes clinical hold on cancer drug trial	16-07-12	RE
Celgene : Wall Street lauds Celgene's $7.2 billion Receptos buy	15-07-15	RE
Celgene : to buy Receptos for $7.2 billion; gains promising drug	15-07-14	RE

Press releases Juno Therapeutics Inc

Juno Therapeutics : Celgene Receives Antitrust Clearance for Juno Acquisition	18-02-21	BU
WeissLaw LLP : Investigates Juno Therapeutics Inc. Acquisition	18-01-24	PR
JUNO THERAPEUTICS, INC. Former SEC Attorney Willie Briscoe Believes the Acquisition by Celgene Corporation May be Unfair to Shareholders	18-01-22	BU
Celgene Corporation : to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy	18-01-22	BU
JUNO THERAPEUTICS INVESTIGATION by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Juno Therapeutics, Inc. - JUNO	18-01-19	BU

More press releases

News in other languages on Juno Therapeutics Inc

Ablynx : Sanofi s'offre une nouvelle biotech en achetant Ablynx 3,9 milliards d'euros	18-01-29
Original-Research: Medigene AG (von EQUITS GmbH): Kaufen	18-01-23
Apple : Wall Street finit en hausse, accord sur le "shutdown"	18-01-22
BOURSE : Wall Street finit à des records après l'accord au Sénat mettant fin au "shutdown"	18-01-22
Barclays : Les Bourses européennes clôturent en hausse, le M&A éclipse le "shutdown"	18-01-22

Managers and Directors - Juno Therapeutics Inc

Managers	Title	Age	Since
Nicole Keith IRC	Investor Relations Contact	-	15-06-30
Jonathan Biller TRE	Treasurer	61	-
Katherine Reynolds Kelly SEC	Corporate Secretary	48	-

Members of the board	Title	Age	Since
Mark Alles BRD	Director/Board Member	64	-
Peter Kellogg BRD	Director/Board Member	67	-

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.30%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW